SANDOZ' LESCOL (FLUVASTATIN) IS FOURTH HMG-CoA REDUCTASE INHIBITOR APPROVED
Executive Summary
Sandoz has the fourth entrant in the HMG-CoA reductase inhibitor cholesterol-lowering market following the approval of Lescol (fluvastatin) by FDA Dec. 31.